Study #2018-0524
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients with Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
AMXT1501, DFMO
Description
A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.